Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CVKDNASDAQ:IMNPNASDAQ:KZRNASDAQ:MRNS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVKDCadrenal Therapeutics$12.29-1.2%$14.24$5.70▼$22.90$24.17M0.9542,596 shs20,178 shsIMNPImmune Pharmaceuticals$0.00$0.00▼$0.48$8.14MN/A12.29 million shsN/AKZRKezar Life Sciences$4.56+1.6%$4.30$3.62▼$9.18$33.33M0.652,097 shs22,529 shsMRNSMarinus Pharmaceuticals$0.55-0.2%$0.55$0.22▼$1.97$30.32M1.031.83 million shs260 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVKDCadrenal Therapeutics-1.21%+19.55%-10.23%-24.00%+1,228,999,900.00%IMNPImmune Pharmaceuticals0.00%0.00%0.00%0.00%0.00%KZRKezar Life Sciences+1.56%+6.79%+3.87%+10.68%-21.26%MRNSMarinus Pharmaceuticals0.00%0.00%0.00%0.00%-54.62%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCVKDCadrenal Therapeutics3.0643 of 5 stars3.55.00.00.01.11.70.6IMNPImmune PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AKZRKezar Life Sciences4.1799 of 5 stars3.23.00.04.60.63.30.6MRNSMarinus Pharmaceuticals2.3853 of 5 stars3.20.00.04.20.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVKDCadrenal Therapeutics 3.00Buy$32.00160.37% UpsideIMNPImmune Pharmaceuticals 0.00N/AN/AN/AKZRKezar Life Sciences 2.33Hold$39.50766.23% UpsideMRNSMarinus Pharmaceuticals 2.40Hold$3.92613.29% UpsideCurrent Analyst Ratings BreakdownLatest IMNP, KZR, CVKD, and MRNS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025CVKDCadrenal TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVKDCadrenal TherapeuticsN/AN/AN/AN/A$4.17 per shareN/AIMNPImmune PharmaceuticalsN/AN/AN/AN/AN/AN/AKZRKezar Life Sciences$7M4.76N/AN/A$16.02 per share0.28MRNSMarinus Pharmaceuticals$30.99M0.98N/AN/A$0.31 per share1.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVKDCadrenal Therapeutics-$10.65M-$9.26N/AN/AN/AN/A-244.94%-181.94%8/6/2025 (Estimated)IMNPImmune PharmaceuticalsN/AN/A0.00N/AN/AN/AN/AN/AN/AKZRKezar Life Sciences-$83.74M-$10.82N/AN/AN/AN/A-61.15%-50.27%8/12/2025 (Estimated)MRNSMarinus Pharmaceuticals-$141.40M-$2.47N/AN/AN/A-446.48%-7,831.35%-120.74%8/11/2025 (Estimated)Latest IMNP, KZR, CVKD, and MRNS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025KZRKezar Life Sciences-$2.56-$2.27+$0.29-$2.27N/AN/A5/8/2025Q1 2025CVKDCadrenal Therapeutics-$1.64-$2.09-$0.45-$2.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCVKDCadrenal TherapeuticsN/AN/AN/AN/AN/AIMNPImmune PharmaceuticalsN/AN/AN/AN/AN/AKZRKezar Life SciencesN/AN/AN/AN/AN/AMRNSMarinus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVKDCadrenal TherapeuticsN/A4.324.32IMNPImmune PharmaceuticalsN/AN/AN/AKZRKezar Life Sciences0.047.097.09MRNSMarinus PharmaceuticalsN/A1.661.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVKDCadrenal Therapeutics7.92%IMNPImmune Pharmaceuticals1.43%KZRKezar Life Sciences67.90%MRNSMarinus Pharmaceuticals98.80%Insider OwnershipCompanyInsider OwnershipCVKDCadrenal Therapeutics48.62%IMNPImmune Pharmaceuticals3.85%KZRKezar Life Sciences10.40%MRNSMarinus Pharmaceuticals5.46%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVKDCadrenal Therapeutics41.97 million1.01 millionNot OptionableIMNPImmune PharmaceuticalsN/A49.31 millionN/ANot OptionableKZRKezar Life Sciences607.31 million6.55 millionNot OptionableMRNSMarinus Pharmaceuticals11055.22 million52.20 millionOptionableIMNP, KZR, CVKD, and MRNS HeadlinesRecent News About These CompaniesMarinus Pharmaceuticals CEO Scott Braunstein sells $167,530 in stockFebruary 11, 2025 | msn.comMarinus Pharmaceuticals director sells shares worth $869January 24, 2025 | msn.comMarinus pharmaceuticals director sells shares for $864January 24, 2025 | msn.comMarinus Pharmaceuticals (MRNS) Upgraded to Buy: Here's What You Should KnowJanuary 10, 2025 | zacks.comSHAREHOLDER NOTICE: Halper Sadeh LLC Investigates MRNS, RHE, SSY, CTV on Behalf of ShareholdersJanuary 9, 2025 | stockhouse.comMarinus Pharmaceuticals Inc (MRNS) Stock: Greater Than Its Current Valuation?January 7, 2025 | bovnews.comBMARINUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marinus Pharmaceuticals, Inc. - MRNSJanuary 6, 2025 | businesswire.comImmedica Pharma to Acquire Marinus Pharmaceuticals in $151 Million DealJanuary 4, 2025 | msn.comMarinus (MRNS) Gets a Hold from Truist FinancialJanuary 4, 2025 | markets.businessinsider.comMarinus Pharmaceuticals Inc (MRNS) Stock: Beyond the Surface of Its Performance?January 4, 2025 | bovnews.comBSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Marinus Pharmaceuticals, Inc. BuyoutJanuary 2, 2025 | markets.businessinsider.comMarinus Pharmaceuticals to be acquired by Immedica for 55c per shareJanuary 1, 2025 | finance.yahoo.comMarinus Pharmaceuticals Inc (MRNS) Stock: Understanding Its Underlying ValueDecember 31, 2024 | bovnews.comBMarinus Pharma to Be Acquired by Immedica in $30 Million DealDecember 31, 2024 | marketwatch.comImmedica to buy rare disease drugmaker Marinus for $151 millionDecember 31, 2024 | chicagobusiness.comCImmedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.December 31, 2024 | finance.yahoo.comImmedica to buy Marinus Pharmaceuticals, stock rises 4%December 31, 2024 | msn.comMarinus Pharma Agrees To $151 Million Acquisition By Immedica: Shares Surge Over 40%December 30, 2024 | benzinga.comMRNS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Marinus Pharmaceuticals, Inc. Is Fair to ShareholdersDecember 30, 2024 | businesswire.comShareholder Alert: Ademi LLP Investigates Whether Marinus Pharmaceuticals, Inc. Is Obtaining a Fair Price for Its Public ShareholdersDecember 30, 2024 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMNP, KZR, CVKD, and MRNS Company DescriptionsCadrenal Therapeutics NASDAQ:CVKD$12.29 -0.15 (-1.21%) Closing price 07/3/2025 02:45 PM EasternExtended Trading$12.64 +0.35 (+2.85%) As of 07/3/2025 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.Immune Pharmaceuticals NASDAQ:IMNPImmune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis. In addition, the company's pain products include AmiKet and AmiKet Nano, a topical analgesic cream containing amitriptyline and ketamine for the treatment of postherpetic neuralgia and diabetic peripheral neuropathy. Further, its oncology portfolio comprises Ceplene, for the maintenance of remission in patients with acute myeloid leukemia in combination with interleukin-2; Azixa and crolibulin that are clinical-stage vascular disrupting agents; NanomAbs, a nanotechnology combination platform; and bispecific antibody platform. Immune Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Englewood Cliffs, New Jersey.Kezar Life Sciences NASDAQ:KZR$4.56 +0.07 (+1.56%) As of 07/3/2025 01:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Marinus Pharmaceuticals NASDAQ:MRNS$0.55 0.00 (-0.16%) As of 02/11/2025Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case How a Government Loan Changes the Game for Plug Power Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.